AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Compugen Announces First-in-Human Trial for COM503 in Advanced Solid Malignancies
ByAinvest
Monday, Oct 6, 2025 7:07 am ET1min read
Compugen, a clinical-stage cancer immunotherapy company, announced that a trial in progress of its first-in-human clinical trial assessing anti-IL18BP antibody, COM503, in advanced solid malignancies will be presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer. The poster presentation will be on Friday, November 7, 2025. Compugen is a pioneer in predictive computational target discovery, powered by AI/ML.
Holon, Israel, September 12, 2025 - Compugen Ltd. (Nasdaq: CGEN; TASE: CGEN), a clinical-stage cancer immunotherapy company, has announced that it will present the results of a first-in-human clinical trial assessing the anti-IL18BP antibody, COM503 (GS-0321), at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place between November 7-9, 2025, in National Harbor, Maryland. The poster presentation, titled "A First in Human Clinical Trial to Assess the Anti-IL18BP Antibody, COM503 (GS-0321) in Participants with Advanced Solid Malignancies," will be presented by Dr. Manish Sharma, MD, Co-Director of Clinical Research, START Midwest, Grand Rapids, on Friday, November 7, 2025.The trial aims to evaluate the safety and efficacy of COM503 in participants with advanced solid malignancies. Compugen, a pioneer in predictive computational target discovery powered by AI/ML, has two proprietary product candidates in Phase 1 development: COM701 and COM902, targeting PVRIG and TIGIT, respectively. Rilvegostomig, a PD-1/TIGIT bispecific antibody derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca. GS-0321, previously known as COM503, is a potential first-in-class, high affinity anti-IL-18 binding protein antibody, currently in Phase 1 development and licensed to Gilead.
Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For more information, please contact Yvonne Naughton, Ph.D., Vice President, Head of Investor Relations and Corporate Communications, at ir@cgen.com or +1 (628) 241-0071.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet